HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that Veridex, LLC, a Johnson & Johnson company, received FDA clearance for the CellSearch™ Circulating Tumor Cell Kit as an aid in the monitoring of patients with metastatic breast cancer. Serial testing for circulating tumor cell (CTC) count should be used in conjunction with other clinical methods for monitoring breast cancer. A CTC count of 5 or more per 7.5 mL of blood at any time during the course of the disease is predictive of shorter progression-free survival and overall survival. Veridex exclusively markets Immunicon’s products in the cellular cancer field.
